• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
DXB
Click for more information
3.33% 43.5¢

DIMERIX LIMITED - News & Media

Market Cap $239.5M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. More

Articles & Videos

Dimerix gains NMPA approval for IND, opening doors to global phase three tudy on FSGS Treatment

Dimerix (ASX:DXB) has secured approval from the Chinese NMPA Centre for Drug Evaluation (CDE) for its IND application.

28 Nov 2023 12:50 (AEDT)

Dimerix secures $10.7m upfront payment from Advanz Pharma

Dimerix (ASX:DXB) has received an initial upfront payment of A$10.7 million as part of its licensing agreement with Advanz Pharma.

06 Nov 2023 15:40 (AEDT)

Dimerix (ASX:DXB) to pocket $2.8m in R&D tax incentive prepayment

Dimerix (ASX:DXB) is set to pocket $2.8 million as a prepayment of a research and development (R&D) tax incentive claim.

17 Feb 2023 10:56 (AEDT)

Dimerix (ASX:DXB) receives FDA approval to include teenagers in kidney disease study

Dimerix (ASX:DXB) has received the green light to include paediatric patients in its ACTION3 study of focal segmental glomerulosclerosis (FSGS).

12 Jan 2023 09:16 (AEDT)



(20min delay)
Last
43.5¢ 		Change
-0.015(3.33%) 		Mkt cap ! $239.5M
Open High Low Value Volume
43.5¢ 43.8¢ 42.0¢ $988.7K 2.301M

Buyers (Bids)

No. Vol. Price($)
1 10000 43.0¢
 

Sellers (Offers)

Price($) Vol. No.
43.5¢ 17061 1
View Market Depth
Last trade - 16.10pm 04/09/2024 (20 minute delay) ?
Last
42.8¢ 		  Change
-0.015 ( 3.95 %)
Open High Low Volume
43.5¢ 43.5¢ 42.0¢ 999771
Last updated 15.59pm 04/09/2024 ?
DXB (ASX) Chart

Top Stories

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

Boss Energy (ASX:BOE) has ramped up production at its Honeymoon project with the first 'NIMCIX' industrial-scale processing asset in place and achieving nameplate capacity.
Is the ASX getting its groove back? Here's 5 IPOs in September to watch After another slow year for IPOs on the ASX, September is looking like it could be a bright spot with 5 newcomers.
SKS secures $20M for extension works on Melbourne data centre SKS Technologies Group Ltd has secured a $20 million contract to add extension works to a data centre in Melbourne's western suburbs.
EBR Systems' heart pacing device on-target to reach the US market EBR Systems Ltd has reached a crucial stage in its efforts to commercialise the WiSE® CRT System for US markets.
GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s Australian GDP for the June quarter came in on-target at 0.2%, the same figure as in two previous quarters.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.